TTrialPathMatch Me to Trials
← Back to trials
RecruitingAtopic DermatitisAtopic Dermatitis (AD)Atopic Dermatitis (Eczema)

Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis

Eligible age

6+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period. Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.

Sponsor: Arcutis Biotherapeutics, Inc.

You may qualify if…

  • ✓ 1. Male or female participants aged 6 years and older.
  • ✓ 2. Clinical diagnosis of moderate to severe atopic dermatitis.
  • ✓ 3. vIGA-AD score of 3 (Moderate) or 4 (Severe) at baseline.
  • ✓ 4. EASI score ≥5 at baseline.
  • ✓ 5. Atopic dermatitis involvement of ≥3% and ≤30% body surface area.
  • ✓ 6. Able and willing to comply with study procedures.
  • ✓ 7. Participant or parent/legal guardian able to provide informed consent/assent.

You may not qualify if…

  • ✕ 1. Uncontrolled medical conditions that could interfere with study participation.
  • ✕ 2. Skin disorders that may confound study assessments.
  • ✕ 3. Active infection requiring systemic treatment.
  • ✕ 4. Known hypersensitivity to roflumilast or formulation components.
  • ✕ 5. Use of prohibited medications within protocol-defined washout periods.
  • ✕ 6. Pregnant or breastfeeding participants.
  • ✕ 7. Participation in another interventional clinical trial within the protocol-defined timeframe.
  • ✕ 8. Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study results.

Where it's recruiting

Alabama

Birmingham

Arkansas

Bryant

Florida

Miami Lakes

Illinois

Chicago

Source: ClinicalTrials.gov · NCT07916480 · last updated 2026-11-06

Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis · TrialPath